Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes

ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes Ann Surg Oncol (2022) 29:8070 https://doi.org/10.1245/s10434-022-12334-1 ASO A UTHOR R EFLECTIONS ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes 1,2,3 1,2 E. Alexa Elder, MD , and Richard White, MD 1 2 Surgical Oncology, Atrium Health, Levine Cancer Institute, Charlotte, NC; Carolinas Medical Center, Levine Cancer Center, Charlotte, NC; Surgical Oncology, Ochsner Medical Center, New Orleans, LA PAST RCB to be predictive in all subtypes, including the hor- mone receptor-positive, HER2-negative group. The RCB The residual cancer burden (RCB) was developed as a provides useful information for patients undergoing standard scoring system to report residual disease burden at neoadjuvant therapy and should be incorporated in the surgery after neoadjuvant chemotherapy. The utility of adjuvant treatment planning for neoadjuvant chemotherapy this scoring system in the context of different breast cancer patients. phenotypes was not well established. DISCLOSURE None. PRESENT REFERENCES In our study, we evaluated the RCB after neoadjuvant 1. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of chemotherapy in different breast cancer phenotypic sub- residual breast cancer burden to predict survival after neoadjuvant types to determine if this was predictive of survival chemotherapy. J Clin Oncol. 2007;25(28):4414–22. 2. Elder EA, Livasy C, Donahue E, et al. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes

Annals of Surgical Oncology , Volume 29 (13) – Dec 1, 2022

ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes

Abstract

Ann Surg Oncol (2022) 29:8070 https://doi.org/10.1245/s10434-022-12334-1 ASO A UTHOR R EFLECTIONS ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes 1,2,3 1,2 E. Alexa Elder, MD , and Richard White, MD 1 2 Surgical Oncology, Atrium Health, Levine Cancer Institute, Charlotte, NC; Carolinas Medical Center, Levine Cancer Center, Charlotte, NC; Surgical Oncology, Ochsner Medical Center, New Orleans, LA PAST RCB to be predictive in all subtypes, including the hor- mone...
Loading next page...
 
/lp/springer-journals/aso-author-reflections-residual-cancer-burden-across-phenotypic-P0Hm6xxv2v

References (3)

Publisher
Springer Journals
Copyright
Copyright © Society of Surgical Oncology 2022
ISSN
1068-9265
eISSN
1534-4681
DOI
10.1245/s10434-022-12334-1
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2022) 29:8070 https://doi.org/10.1245/s10434-022-12334-1 ASO A UTHOR R EFLECTIONS ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes 1,2,3 1,2 E. Alexa Elder, MD , and Richard White, MD 1 2 Surgical Oncology, Atrium Health, Levine Cancer Institute, Charlotte, NC; Carolinas Medical Center, Levine Cancer Center, Charlotte, NC; Surgical Oncology, Ochsner Medical Center, New Orleans, LA PAST RCB to be predictive in all subtypes, including the hor- mone receptor-positive, HER2-negative group. The RCB The residual cancer burden (RCB) was developed as a provides useful information for patients undergoing standard scoring system to report residual disease burden at neoadjuvant therapy and should be incorporated in the surgery after neoadjuvant chemotherapy. The utility of adjuvant treatment planning for neoadjuvant chemotherapy this scoring system in the context of different breast cancer patients. phenotypes was not well established. DISCLOSURE None. PRESENT REFERENCES In our study, we evaluated the RCB after neoadjuvant 1. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of chemotherapy in different breast cancer phenotypic sub- residual breast cancer burden to predict survival after neoadjuvant types to determine if this was predictive of survival chemotherapy. J Clin Oncol. 2007;25(28):4414–22. 2. Elder EA, Livasy C, Donahue E, et al.

Journal

Annals of Surgical OncologySpringer Journals

Published: Dec 1, 2022

There are no references for this article.